These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 12587536)
1. Circulating nitric oxide changes throughout the menstrual cycle in healthy women and women affected by pathological hyperprolactinemia on dopamine agonist therapy. Giusti M; Fazzuoli L; Cavallero D; Valenti S Gynecol Endocrinol; 2002 Oct; 16(5):407-12. PubMed ID: 12587536 [TBL] [Abstract][Full Text] [Related]
2. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830 [TBL] [Abstract][Full Text] [Related]
3. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175 [TBL] [Abstract][Full Text] [Related]
4. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment. Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874 [TBL] [Abstract][Full Text] [Related]
5. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study. Höfle G; Gasser R; Mohsenipour I; Finkenstedt G Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362 [TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of serum prolactin throughout the menstrual cycle and pregnancy in hyperprolactinemic women with normal ovarian function. Larrea F; Escorza A; Valero A; Hernandez L; Cravioto MC; Diaz-Sanchez V J Clin Endocrinol Metab; 1989 May; 68(5):982-7. PubMed ID: 2715295 [TBL] [Abstract][Full Text] [Related]
7. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824 [TBL] [Abstract][Full Text] [Related]
8. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients. Lu CC; Hsieh CJ Kaohsiung J Med Sci; 2012 Feb; 28(2):94-9. PubMed ID: 22313536 [TBL] [Abstract][Full Text] [Related]
9. Prolactin levels in infertility and bromocriptine therapy in hyperprolactinaemia. Prathibha D; Govardhani M; Krishna PT J Indian Med Assoc; 1994 Dec; 92(12):397-9. PubMed ID: 7876578 [TBL] [Abstract][Full Text] [Related]
10. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline. Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770 [TBL] [Abstract][Full Text] [Related]
11. Atypical estradiol secretion and ovulation patterns caused by luteal out-of-phase (LOOP) events underlying irregular ovulatory menstrual cycles in the menopausal transition. Hale GE; Hughes CL; Burger HG; Robertson DM; Fraser IS Menopause; 2009; 16(1):50-9. PubMed ID: 18978637 [TBL] [Abstract][Full Text] [Related]
12. Transient hyperprolactinemia in infertile women with luteal phase deficiency. Huang KE; Bonfiglio TA; Muechler EK Obstet Gynecol; 1991 Oct; 78(4):651-5. PubMed ID: 1923170 [TBL] [Abstract][Full Text] [Related]
13. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders. Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999 [TBL] [Abstract][Full Text] [Related]